-
Mashup Score: 0Fruquintinib: A New Frontier in Colorectal Cancer Therapy - 9 month(s) ago
Fruquintinib, a novel targeted therapy, has emerged as a potential game-changer in the treatment landscape of metastatic colorectal cancer. The FRESCO-2 study – This study’s findings have expanded our knowledge about the potential use of fruquintinib in the treatment of advanced colorectal cancer, demonstrat…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Fruquintinib Plus Toripalimab Is an Effective Third-Line Treatment of Advanced Colorectal Cancer | Docwire News - 10 month(s) ago
Fruquintinib combined with the anti-programmed death-1 antibody toripalimab is effective in treating advanced colon cancer.
Source: Docwire NewsCategories: Latest Headlines, Partners & KOLsTweet-
A recent study suggested that fruquintinib combined with toripalimab has a better effect compared with fruquintinib alone in the third-line treatment of patients with refractory metastatic advanced #colorectalcancer. #fruquintinib https://t.co/pNTtG9UYLe https://t.co/ZWrJqt50PD
-
-
Mashup Score: 0
The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The #FDA has set a priority review for #fruquintinib, designed to target multiple receptors that could address an unmet need in metastatic #ColorectalCancer, while data from @ASCO confirms its safety. Read more: https://t.co/7GHIOsbhiK https://t.co/0GZpxRAMar
-
-
Mashup Score: 2
The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced colorectal cancer. As part of the study, an analysis was conducted to assess the adverse events of special interest associated with fruquintinib treatment. Cathy Eng, MD, FACP, FASC…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 ASCO 2023 Colorectal Cancer 🎉 ➡️ How was the #FRESCO2 study designed, and what were the key objectives and endpoints assessed in the study? 🔬 @CathyEngMD @VUMCHealth @VUMC_Cancer #mCRC #Fruquintinib 🔗 https://t.co/Y5For2F5N9 https://t.co/ohrATVrgFn
-
-
Mashup Score: 0FDA Grants Priority Review to NDA of Fruquintinib for Metastatic CRC - 12 month(s) ago
If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has granted priority review of the NDA for #fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer. #crcsm https://t.co/sXRDpwSoBw
-
-
Mashup Score: 22
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Hem/Oncs, Latest HeadlinesTweet-
w/ @CathyEngMD, we 🗣 the Rx algorithm for #ColonCancer and the pending #Fruquintinib approval. Full Int: - https://t.co/LNQinz3t9O - Also on the “Oncology Brothers” podcast 🎙️ @OncoAlert @GIcancerDoc #gism @HemOncFellows @VUMCHemOnc #crcsm #OncTwitter #MedTwitter #OncEd https://t.co/WrciRcEML0
-
-
Mashup Score: 0FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer Treatment - 1 year(s) ago
Soon, the FDA will be considering fruquintinib for approval to treat patients with refractory metastatic colorectal cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A rolling submission of a new drug application has been completed for #fruquintinib for the treatment of patients with refractory #mCRC. #crcsm #FDA https://t.co/mvI8mKoqIm
-
#Fruquintinib's promise in the battle against #cancer Dive into the specifics and the #FRESCO-2 study in our in-depth article with an interview with Dr. Cathy Eng, MD, FACP, FASCO during #ASCO23. @CathyEngMD @VUMChealth https://t.co/7eLmShChqQ